SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
SystImmune是一個家正處在臨床治療研究階段中，的先進生物體制藥廠有限工司，悉心于開放代替癌癥復發治療方法的一種新型雙特女性朋友、多特女性朋友免疫抗體陽性及免疫抗體陽性食用的藥物偶聯物（ADCs）。有限工司現如今否認擬任Jonathan Cheng碩士生為SystImmune現任首席ceo醫學研究官。在注入SystImmune先前，Cheng碩士生在百時美施貴寶扮演中高級副總經理裁兼癌癥轉型行政主管，承當標準化管理抗癌癥管路的臨床治療研究后續開放。完成此前擬任，Cheng 碩士生繼任了Martin Olivo 碩士生，二者為去尋找其他轉型一次機會已撤出SystImmune。
“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Ｅxecutive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”
SystImmune總裁執行命令官Jie D'Elia碩士生表達出來：“我很愉快并誠邀Cheng碩士生填加我的的老板精英公司。他在國內惡性腫瘤中成藥發展方面的工程專業析出和對服務行業監管機構的感觸頗深看待，將速度SystImmune的地埋管施工進度，并舉一部力促我的對病號緩解的組織變革。我謹代表英語SystImmune精英公司，向Martin Olivo碩士生對公的司的貢獻表達出來很深的感激。我的期望他在未來是什么所有的順當。”
Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Ｅxecutive leadership team.”
SystImmune董事局長朱義碩士顯示：“Cheng碩士在腫癌用藥聯合開發范疇有很多的職業 信息和非凡的的營業收入，他的添加讓SystImmune官員銷售團隊變得穩步發展。”
Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.
Cheng博土的角色炫舞時尚走向藥業這個業內和學術性交流界，在驅動腸癌晚期改善地方不斷能夠了十足的上級上級領導人業務能力和友好。在他的上級上級領導人下，BMS設計規劃并市場銷售了多種多樣根本類藥物，包涵Nivolumab、Ipilimumab、Relatlimab和Repotrectinib。他的戰術卓識，增加了該廠家內部組織成品線包括戰略合作供水管道的競爭性力。在建立BMS已經，Cheng博土為默沙東腫癌監床分析總經理裁，并上級上級領導人管理團隊要先拿到Pembrolizumab和Lenvatinib在二個腫癌融入癥的市場銷售獲準。在加入藥業這個業內已經，Cheng博土在 Fox Chase 腸癌晚期重點得到成就的學術性交流炫舞時尚。他當做腫癌基本材料生物工程學的首席總裁分析員，展開了打開性的分析，并造成150 好幾份默認稿件和引言。Cheng博土換取馬凱巨型學學土雙學位學歷和明尼蘇達綜合大學醫美博土雙學位學歷。
For further information, please contact: info@systimmune.com
如需更加個人信息，請鏈接:info@systimmune.com
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
關羽SystImmune
SystImmune一家設在華盛頓州雷德蒙德的占據診療時段的生物工程體藥業手機平臺。該手機平臺精益求精于根據其成熟穩重的制劑激發建設手機平臺，激發建設自主創新的胃癌療法技巧，還有雙特喜歡的人、多特喜歡的人免疫抵抗能力及免疫抵抗能力制劑偶聯物（ADCs）。SystImmune在三維線瘤和血漿病的層面的個診療耐壓檢測時段均享有管網和新技術儲備量。不光稍后做出的診療耐壓檢測外，手機平臺還享有整體知名度強大的診療前管網，還有占據發展時段或IND時段的隱藏胃癌療法制劑，體現著手機平臺在生物工程體藥業激發建設的層面的世界領先知名度。
